Financial statements Ursapharm Poland
Balance sheet of Ursapharm Poland
Company age:
Age:
15 y. 4 m. 11 d.
Share capital:
Share capital:
50 000 PLN
Balance sheet data of URSAPHARM POLAND
|
Year
|
2019
|
2020
|
2021
|
2023
|
|---|---|---|---|---|
| Total assets | 34 844 425,46 | 37 909 099,45 | 40 087 428,06 | 26 250 216,52 |
| A. Fixed assets | 80 549,95 | 75 799,08 | 96 557,71 | 153 331,57 |
| B. Current assets | 34 763 875,51 | 37 833 300,37 | 39 990 870,35 | 26 096 884,95 |
| C. Share capital contributions (basic funds) | 0,00 | 0,00 | 0,00 | 0,00 |
| D. Own shares (stocks) | 0,00 | 0,00 | 0,00 | 0,00 |
| Total liabilities | 34 844 425,46 | 37 909 099,45 | 40 087 428,06 | 26 250 216,52 |
| A. Equity | 29 068 915,60 | 35 477 775,52 | 36 911 080,43 | 23 765 368,78 |
| B. Liabilities and provisions for liabilities | 5 775 509,86 | 2 431 323,93 | 3 176 347,63 | 2 484 847,74 |
| I. Long-term liabilities | 0,00 | 0,00 | 0,00 | 0,00 |
| II. Short-term liabilities | 4 760 023,59 | 1 404 230,17 | 2 151 226,26 | 1 189 275,92 |
Financial data is automatically retrieved from the EKRS webpage of the Ministry of Justice.
- Fixed Assets - Assets held for a longer period, typically longer than a year, such as real estate or machinery.
- Current Assets - Assets intended to be used or sold within a year, such as inventory, receivables, and cash.
- Equity - The net value of a company's assets, representing the difference between its assets and liabilities.
- Long-Term Liabilities - Financial obligations to be repaid over a period longer than a year, such as loans or bonds.
- Short-Term Liabilities - Financial obligations to be repaid within a year, such as payables to suppliers or short-term loans.
- Reserve Capital - A portion of equity set aside for specific purposes, such as covering losses or business development.